Press Releases

Why Did Ann Wagner Vote Against Legislation to Lower Prescription Drug Prices for Missourians?

Oct 19, 2020

H.R.3 would have allowed Medicare to negotiate prices for up to 250 of the most expensive drugs

Wagner has taken over $387,000 from Big Pharma and health insurance corporate PACs

With two weeks until Election Day, Congresswoman Ann Wagner and her Big Money allies are attempting to distract voters from her record of selling out Missouri families. Throughout her tenure in Congress, Ann Wagner has become one of Big Pharma’s closest allies, and her voting record proves it. She has favored the industry over the health and safety of her constituents by voting against legislation like H.R. 3, the Lower Prescription Drug Costs Now Act, that would have significantly lowered Missourians’ prescription drug prices.

“It’s not hard to figure out why Congresswoman Wagner votes the way she does. All you have to do is follow the money: over the course of her political career, Wagner has accepted over $387,000 from Big Pharma and health insurance corporate PACs. She supports these industries’ bottom line in Congress at the expense of Missourians because her big donors demand it,” said End Citizens United President Tiffany Muller. “Unlike Wagner, Missouri families can trust Jill Schupp to fight for lower prescription drug prices because she refuses to take a dime of their corporate PAC money.”

Congresswoman Wagner voted against the Lower Prescription Drug Costs Now Act (H.R. 3,) a bold, critical bill that would: 

  • Give Medicare new powers to negotiate annual prices up to 250 of the most expensive drugs on the market and create powerful new tools to force drug companies to the table to agree to real price reductions, while ensuring seniors never lose access to the prescriptions they need.

  • Make the lower drug prices negotiated by Medicare available to Americans with private insurance, not just Medicare beneficiaries.

  • Stop drug companies from ripping off Americans while charging other countries less for the same drugs, limiting the maximum price for any negotiated drug to be in line with the average price in countries like ours, where drug companies charge less for the same drugs – and admit they still make a profit.

  • Create a new, $2,000 out-of-pocket limit on prescription drug costs for Medicare beneficiaries, and reverse years of unfair price hikes above inflation across thousands of drugs in Medicare.

  • Reinvest nearly half a trillion in savings into expanding Medicare coverage for dental, vision, and hearing services.

###